|
Jun 30
|
Did Down-And-Out Moderna Just Unlock The Key To Its Future Profitability?
|
|
Jun 30
|
Sector Update: Health Care Stocks Higher Late Afternoon
|
|
Jun 30
|
Sector Update: Health Care Stocks Advance Monday Afternoon
|
|
Jun 30
|
Moderna’s mRNA flu shot outperforms current standard at Phase III
|
|
Jun 30
|
Moderna Stock Is Climbing on Trial Data. A Flu-Covid Vaccine Isn’t a Sure Thing.
|
|
Jun 30
|
Top Stock Movers Now: Hewlett Packard Enterprise, Moderna, Tesla, and More
|
|
Jun 30
|
Top Midday Stories: Hewlett Packard, Juniper Settle Antitrust Suit With DOJ; Home Depot Unit Acquires GMS for $5.5 Billion
|
|
Jun 30
|
Moderna Shares Jump With Positive Test Results for MRNA Flu Vaccine
|
|
Jun 30
|
Moderna Says Flu Vaccine Candidate More Effective Than Standard Licensed Shots
|
|
Jun 30
|
Stocks See Support as Signs of Trade Progress Boost Market Sentiment
|
|
Jun 30
|
Solar stocks, Moderna, HPE: Trending Tickers
|
|
Jun 30
|
Exchange-Traded Funds, Equity Futures Edge Higher Pre-Bell Monday Amid Hopes of Smoother Canada Relations
|
|
Jun 30
|
Vertex Down Around 9% in Three Months: Should You Buy, Sell or Hold the Stock?
|
|
Jun 30
|
Moderna Announces Positive Phase 3 Results for Seasonal Influenza Vaccine
|
|
Jun 27
|
Cancer Vaccine (Preventative, Therapeutic) Market Research 2025 with Analyst Recommendations-Leveraging AI and Bioinformatics for Precision Development / Pursue Fast-Track and Orphan Drug Designations
|
|
Jun 26
|
Moderna (MRNA) Outperforms Broader Market: What You Need to Know
|
|
Jun 26
|
The Top 5 Analyst Questions From Moderna’s Q1 Earnings Call
|
|
Jun 25
|
Seeking a Cure for Sickly Corporate Governance at SinoVac
|
|
Jun 25
|
Moderna (MRNA): Buy, Sell, or Hold Post Q1 Earnings?
|
|
Jun 24
|
Moderna RSV Vaccine Gains Expanded FDA Approval for Younger Adults
|